Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Evommune Inc (EVMN)

82 + Investors. Track Smart Money conviction in EVMN. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +24
Streak
2Q ▲
Buyers last Q
73%

Smart Money Signals — EVMN

Based on 82 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added EVMN than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
82 hedge funds hold EVMN right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +8100% more funds vs a year ago

fund count last 6Q
+81 new funds entered over the past year (+8100% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 73% buying

61 buying23 selling
Last quarter: 61 funds were net buyers (36 opened a brand new position + 25 added to an existing one). Only 23 were sellers (11 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.
⚠️

Fewer new buyers each quarter (-21 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 0 → 0 → 57 → 36. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔄

Mostly new holders — 96% entered in last year

■ 4% conviction (2yr+) ■ 0% medium ■ 96% new
Only 3 funds (4%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💰

Value +63% but shares only +22% — price-driven

Value
+62%
Shares
+21%
Last quarter: the total dollar value of institutional holdings rose +63%, but actual share count only changed +22%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
➡️

Steady discovery — ~36 new funds/quarter

0 → 0 → 0 → 57 → 36 new funds/Q
New funds entering each quarter: 0 → 0 → 57 → 36. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🌱

Early stage — 95% of holders entered in last year

■ 5% veterans ■ 0% 1-2yr ■ 95% new
Of 82 current holders: 78 (95%) entered in the past year, only 4 (5%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
📋

Smaller funds dominant — 11% AUM from top-100

11% from top-100 AUM funds
23 of 82 holders rank in the top 100 by AUM, but together hold only 11% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
7.4
out of 10
High Exit Risk
Exit risk score 7.4/10 — multiple crowding signals converge. Institutional ownership is at 100% of its all-time high — near peak crowding. Crowded trades can unwind fast — a single catalyst can trigger a cascade.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — EVMN

In 2026 Q1, 61 hedge funds were net buyers of EVMN (36 opened a new position, 25 added to an existing one), while 23 reduced or exited (11 trimmed, 12 sold completely) — a 73% buyer ratio, indicating clear institutional accumulation. Net buying has persisted for two consecutive quarters, a positive momentum signal. Net fund flow last quarter: +24 funds (more new holders than closures). Total institutional holders: 82.

Hedge Fund Ownership: EVMN

How many hedge funds hold EVMN — quarterly history vs. share price
Quarterly hedge fund ownership of EVMN vs. share price

Market Analysis: EVMN

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: EVMN

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Evommune Inc (EVMN) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much EVMN has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 47d ago
EVMN
+10.2%
XLV
+5.5%

EVMN outperformed XLV by +4.7% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 2d ago
EVMN
+0.0%
XLV
+0.0%

Since the filing became public, EVMN outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

11 top-rated funds 6 high-conviction
Consensus
4.7
/ 10
breadth
×
Elite
3.2
/ 10
conviction
Hedge Fund Positioning: EVMN
2026 Q2 Stats Unlock in 3 days 82 + Investors

Track Smart Money conviction in EVMN. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 82 58 41.38%
13F Shares 33M 27M 21.74%
Total Value $736M $452M 62.61%
New Positions 36 58 -22
Increased Positions 25 0 +25
Closed Positions 12 0 +12
Reduced Positions 11 0 +11
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: EVMN

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

82 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in EVMN. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 EVMN holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Nan Fung Group Holdings Ltd 14.56% 1,441,032 $19.2M
2 Andera Partners 8.96% 1,391,990 $18.5M
3 Pivotal bioVenture Partners Investment Advisor LLC 8.32% 1,926,943 $25.6M
4 EQT Fund Management S.a r.l. 8.15% 5,288,313 $70.3M
5 Velan Capital Investment Management LP 3.65% 451,255 $6.0M
6 Defilade Capital Management, L.P. 1.41% 793,145 $10.5M
7 Great Point Partners LLC 0.82% 325,000 $4.3M
8 NEXTBio Capital Management LP 0.73% 119,063 $1.6M
9 Ra Capital Management, L.P. 0.40% 3,494,638 $46.4M
10 Blue Owl Capital Holdings LP 0.36% 180,000 $2.4M
11 Vestal Point Capital, LP 0.31% 1,000,000 $13.3M
12 Affinity Asset Advisors, LLC 0.30% 500,100 $6.6M
13 Eventide Asset Management, LLC 0.21% 1,209,129 $16.1M
14 Rtw Investments, LP 0.17% 1,502,235 $20.0M
15 Avidity Partners Management LP 0.16% 75,000 $997K
16 Eversept Partners, LP 0.12% 174,460 $2.3M
17 ADAR1 Capital Management, LLC 0.06% 104,035 $1.4M
18 Baker BROS. Advisors LP 0.06% 847,390 $11.3M
19 Virtus Investment Advisers, LLC 0.05% 16,500 $219K
20 Seven Grand Managers, LLC 0.05% 90,568 $1.2M
21 Orbimed Advisors LLC 0.04% 161,000 $2.1M
22 Sphera Funds Management LTD. 0.04% 22,632 $301K
23 Longaeva Partners L.P. 0.03% 116,611 $1.5M
24 Freestone Grove Partners LP 0.03% 306,328 $4.1M
25 Alyeska Investment Group, L.P. 0.02% 704,425 $9.4M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Evommune Inc (EVMN)

What does the Smart Money Trend signal show for EVMN?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added EVMN than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for EVMN?

More buyers than sellers — 73% buying: Last quarter: 61 funds were net buyers (36 opened a brand new position + 25 added to an existing one). Only 23 were sellers (11 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for EVMN holders?

Smaller funds dominant — 11% AUM from top-100: 23 of 82 holders rank in the top 100 by AUM, but together hold only 11% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held EVMN?

Mostly new holders — 96% entered in last year: Only 3 funds (4%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Evommune Inc (EVMN) following the 2026 Q2 hedge fund 13F filings?

As of today, EVMN has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), EVMN has gained +10.2% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →